Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 8/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | USP14 | P54578 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5662801 | 0.87 | USP30 (0.39) | USP30DPP4ALDH1A1SMN1; SMN2KDM1A | |
| SCHEMBL4757474 | 0.87 | KDM4E (0.39) | USP30CHRM4DPP4DPP9ALDH1A1 | |
| SCHEMBL5661256 | 0.85 | CCR1 (0.41) | ALDH1A1SMN1; SMN2KDM1A | |
| SCHEMBL4706419 | 0.78 | SLC6A9 (0.44) | CHRM4DPP4DPP8DPP9DPP7 | |
| SCHEMBL22099636 | 0.76 | NOTUM (0.53) | CHRM4DPP4DPP8DPP9DPP7 | |
| SCHEMBL5663492 | 0.74 | USP30 (0.39) | USP30SMN1; SMN2KDM1A | |
| SCHEMBL4705699 | 0.74 | SLC6A9 (0.40) | CHRM4DPP4DPP8DPP9DPP7 | |
| SCHEMBL5659856 | 0.74 | HTT (0.39) | CHRM4ALDH1A1SMN1; SMN2 | |
| SCHEMBL4759948 | 0.73 | SLC6A9 (0.46) | USP30SLC6A9KDM1AKCNH2 | |
| SCHEMBL22570962 | 0.72 | CHRM4 (0.47) | CHRM4SLC6A9ALDH1A1SMN1; SMN2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979318-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070197530-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-23 | — | — | US | disclosed |
| WO-2007089683-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197530-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, HSD17B11, CYP11B1 | USP30 2736/4885CHRM4 4766/4885DPP4 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.